Document is current
Any future updates will be listed below
-
Authors
Löhr, Mario
Freitag, Benjamin
Technau, Antje
Krauss, Jürgen
Monoranu, Camelia-Maria
Rachor, Johannes
Lutz, Manfred B.
Hagemann, Carsten
Kessler, Almuth F.
Linsenmann, Thomas
Wölfl, Matthias
Ernestus, Ralf-Ingo
Engelhardt, Sabrina
Gelbrich, Götz
Schlegel, Paul G.
Eyrich, Matthias
-
Funding
Funding for this research was provided by:
Parents’ Initiative Group for Children with Leukemia- and Solid Tumors Würzburg e.V.
Tour of Hope Foundation e.V.
Interdisziplinäres Zentrum für Klinische Forschung Wuerzburg (B-107)
Interdisziplinäres Zentrum für Klinische Forschung Wuerzburg (B-107)
Interdisziplinäres Zentrum für Klinische Forschung Wuerzburg (B-107)
Deutsche Kinderkrebsstiftung (DKKS 2015.15)
Vogel-Stiftung Dr. Eckernkamp
Promotionsstipendium der Medizinischen Fakultät
- License Information
-
More Information
Article History
Received: 16 December 2017
Accepted: 20 July 2018
First Online: 27 July 2018
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: The biomarker study has been reviewed and approved bythe Ethikkommission bei der Medizinischen Fakultät der Universität Würzburg(# 135/09). All patients were treated after informed consent, in case of minors by their guardians. The clinical trialHIT-HGG Rez Immunovac trial(Eudra-CT: 2013-000419-26) is performed in accordance with the declaration of Helsinki. It was reviewed and approved by theEthikkommission bei der Medizinischen Fakultät der Universität Würzburg(# 175/16_ff), and is currently recruiting patients.
: All participants of the biomarker study (#135/09) as well as the patients treated within the pilot phase of the HIT-HGG Rez Immunovac trial (#175/16_ff) were only sampled or treated after receiving informed consent from the patients or their guardians.
